Harvard Catalyst has transcended the boundaries long imposed by the historical, corporate, and cultural independence of Harvard and its 17 affiliated academic healthcare centers (AHCs) to bring cross-disciplinary investigators together to collaborate and form teams to conduct clinical and translational (CT) research. Today education, resources and services are jointly planned, executed, broadly shared, and evaluated with the common goal of improving the quality, speed, safety, efficiency and cost across the entire spectrum of CT research. Ongoing CTSA recognition coupled with the opportunity to be a significant participant in the Consortium will enable Harvard Catalyst to implement its vision and strategic plan. First, we will convene investigators from our 11 schools and 17 AHCs to identify and prioritize the most important opportunities in CT research. We will help them to connect with one another to form cross-disciplinary teams and then provide them with the opportunities, incentives, and access to outstanding education and resources in an environment that values innovation, collaboration, and team science. Second, we will work with our schools and AHCs to build and grow an environment where discoveries are rapidly and efficiently translated to improve human health. Simply stated, Harvard Catalyst strives to be a Convener, Connector and Catalyst to hasten and improve the quality CT research. To this end, we have structured our academic home to create an integrated pathway of education, training, and career development and to provide a full portfolio of innovative resources and services to address identified gaps and investigator needs. Within five years, our achievements will include: 1) a continuous, sustainable, robust pipeline of future team leaders across all CT domains;2) implementation of SHRINE-CT coupled with resolution of regulatory hurdles to allow nvestigators to rapidly identify, contact, and accrue specific patients to clinical trials across institutions and throughout the Consortium;3) establishment of a team of experts who will reduce the barriers to engagement and entry to human experimentation thereby growing and diversifying the community of investigators who conduct CT research;4) infrastructure to provide all CT investigators access to the resources they need to conduct human clinical studies wherever their work is best done;and 5) systematic investigation of innovative methodologies to incentivize, form and nurture teams to create new preventions, biomarkers, and therapeutics. These achievements will continue the transformation of CT research at Harvard with the goal of catalyzing a """"""""One Harvard"""""""" community and culture committed to improving health.
The Harvard Clinical and Translational Science Center supports an academic home that creates an integrated research and training environment across Harvard Medical School and its partner institutions in order to improve human health. It provides and/or creates access to resources and services to support all steps of clinical research across the full spectrum of clinical and translational research, and facilitates the training and career development of the translational research workforce.
|Moghari, Mehdi H; Barthur, Ashita; Amaral, Maria E et al. (2018) Free-breathing whole-heart 3D cine magnetic resonance imaging with prospective respiratory motion compensation. Magn Reson Med 80:181-189|
|Khera, Amit V; Chaffin, Mark; Aragam, Krishna G et al. (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50:1219-1224|
|Shakir, Mubeen; Armstrong, Katrina; Wasfy, Jason H (2018) Could Pay-for-Performance Worsen Health Disparities? J Gen Intern Med 33:567-569|
|Stachler, Matthew D; Camarda, Nicholas D; Deitrick, Christopher et al. (2018) Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 155:156-167|
|Spring, Laura; Niemierko, Andrzej; Haddad, Stephanie et al. (2018) Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat 172:733-740|
|Bebell, Lisa M; Ngonzi, Joseph; Siedner, Mark J et al. (2018) HIV Infection and risk of postpartum infection, complications and mortality in rural Uganda. AIDS Care 30:943-953|
|Hamada, Tsuyoshi; Liu, Li; Nowak, Jonathan A et al. (2018) Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. Eur J Cancer 103:98-107|
|Vassy, Jason L; Ho, Yuk-Lam; Honerlaw, Jacqueline et al. (2018) Yield and bias in defining a cohort study baseline from electronic health record data. J Biomed Inform 78:54-59|
|Natarajan, Pradeep; Peloso, Gina M; Zekavat, Seyedeh Maryam et al. (2018) Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. Nat Commun 9:3391|
|McCarthy, Cian P; Bhambhani, Vijeta; Pomerantsev, Eugene et al. (2018) In-hospital outcomes in invasively managed acute myocardial infarction patients who receive morphine. J Interv Cardiol 31:150-158|
Showing the most recent 10 out of 206 publications